Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low – What’s Next?

Janux Therapeutics, Inc. (NASDAQ:JANX)’s stock price hit a new 52-week low on Tuesday. The company traded as low as $11.88 and last traded at $11.9630, with a volume of 726,282 shares trading hands. The stock had previously closed at $12.76.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on JANX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Friday, October 16th. Stifel Nicolaus set a $35.00 target price on shares of Janux Therapeutics in a research note on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. Wedbush increased their target price on shares of Janux Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.92.

Janux Therapeutics Stock Down 5.1%

The company has a market cap of $740.41 million, a P/E ratio of -7.71 and a beta of 2.44. The firm has a fifty day moving average price of $17.39 and a 200 day moving average price of $15.41.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13. The company had revenue of $9.29 million for the quarter, compared to the consensus estimate of $8.03 million. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.70 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Diversified Trust Co lifted its holdings in Janux Therapeutics by 3.5% during the third quarter. Diversified Trust Co now owns 17,429 shares of the company’s stock worth $301,000 after acquiring an additional 588 shares in the last quarter. GAMMA Investing LLC grew its stake in Janux Therapeutics by 67.4% in the third quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after acquiring an additional 661 shares during the period. Versant Capital Management Inc increased its holdings in shares of Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after acquiring an additional 784 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in shares of Janux Therapeutics by 8.8% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 12,350 shares of the company’s stock worth $213,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Quantinno Capital Management LP raised its position in shares of Janux Therapeutics by 7.6% during the first quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after purchasing an additional 1,846 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.